FDA Grants Medivir's MIV-711 Orphan Drug Designation for Osteogenesis Imperfecta Treatment
Key Insights
Medivir AB announced that the FDA has granted Orphan Drug Designation to MIV-711, a selective cathepsin K (search) inhibitor, for treating osteogenesis imperfecta (search), a rare genetic bone disorder.
The designation provides significant regulatory benefits including tax credits, FDA fee exemptions, and seven years of marketing exclusivity for this rare disease affecting fewer than 200,000 Americans.
Preclinical studies in OI-specific animal models demonstrated that MIV-711 significantly improved bone strength, quality, and morphology in a dose-dependent manner.
Medivir AB announced that the FDA has granted Orphan Drug Designation (ODD) to MIV-711, a selective cathepsin K (search) inhibitor, for the treatment of osteogenesis imperfecta (search) (OI). The Stockholm-based pharmaceutical company, which focuses on developing innovative cancer treatments, received this designation for addressing a rare genetic disorder that affects bone formation and strength.
Regulatory Benefits and Market Impact
Orphan drug designation is granted to investigational treatments for rare diseases affecting fewer than 200,000 people in the United States. The designation provides substantial regulatory and commercial advantages, including assistance in drug development, tax credits, exemptions from FDA fees, and seven years of marketing exclusivity upon approval.
"We are delighted that MIV-711 has been granted ODD by the FDA, which strengthens the evidence base for its ability to positively impact bone remodeling and its potential to treat bone-related disorders," said Jens Lindberg, CEO of Medivir.
Addressing Critical Unmet Medical Need
Osteogenesis imperfecta (search) is a rare genetic disorder that negatively affects the body's ability to produce type I collagen, leading to bone fragility that causes bone deformities and frequent fractures, often with minimal or no trauma. The condition presents multiple subtypes ranging from mild to severe, with the most severe forms being incompatible with life, resulting in patient death shortly after birth due to multiple fractures.
Currently, there are no approved treatment options for patients diagnosed with OI, representing a significant unmet medical need in this patient population.
Preclinical Evidence Supporting Designation
To obtain ODD, supportive data suggesting drug effectiveness in the target disease is required. MIV-711 demonstrated significant and dose-dependent positive impact on bone strength and quality as well as bone morphology in OI-specific animal models, supporting potential benefit in treating patients with OI.
Clinical data from osteoarthritis (search) studies further support that MIV-711 has a positive effect in preventing bone degradation, which translates to potential clinical benefit in OI patients.
Mechanism of Action
MIV-711 inhibits cathepsin K (search), the main enzyme by which osteoclasts involved in bone resorption and cartilage degradation cleave collagen in the bone matrix. Cathepsin K inhibition protects damaged bone by reducing bone resorption and promoting bone formation, thereby addressing the key mechanisms causing pathological changes in OI with potential to minimize long-term negative effects.
The drug candidate is designed to restore the balance between excessive bone resorption and bone formation with the aim of preventing fractures and bone deformities. By inhibiting cathepsin K (search) and the increased or excessive activity of osteoclasts, MIV-711 has the potential to counteract excessive bone resorption.